Patients receiving neoadjuvant chemoimmunotherapy NCI show improved pathological responses and disease-free survival DFS compared to those receiving Neoadjuvant chemotherapy NC. Their clinicopathological characteristics were reviewed and analyzed. The percentage of patients achieving a major pathologic response was The percentage of patients with pathologic complete response was Lung cancer ranks as the most commonly diagnosed cancer and stands as the leading cause of cancer-related deaths worldwide, accounting for approximately 2.
Due to the high heterogeneity of locally advanced stage III lung cancers, multidisciplinary teams manage the appropriate curative treatment. Neoadjuvant treatment followed by surgery is the standard of care for potentially resectable tumors. Neoadjuvant treatment has several advantages, including improved pre-surgical tolerance, tumor downstaging, an earlier opportunity to eradicate micrometastases, improved R0 resection rate, and increased knowledge of drug sensitivity 5 , 6.
Neoadjuvant chemotherapy NC is more beneficial for survival than surgery alone hazard ratio [HR]: 0. Immune checkpoints are molecules of co-inhibitory signaling pathways that maintain immune tolerance; cancer cells often utilize them to evade immunosurveillance 9. ICIs relieve repression of antitumor immune responses by altering the interactions between T cells and either antigen-presenting cells or tumor cells Immunotherapy has recently revolutionized the treatment of NSCLC from late to early stages, becoming an integral part of lung cancer treatment.
In addition to providing survival benefits for patients with advanced disease, ICIs can also treat relatively early-stage diseases. Patients who received durvalumab showed improved progression-free survival PFS compared with placebo Neoadjuvant chemoimmunotherapy NCI is increasingly being studied to identify better treatment options. We are attempting to apply NCI to transfer these patients from inoperable to operable, enabling advanced patients to achieve long-term survival and a potential clinical cure.
Chemoimmunotherapy is effective as a novel approach to neoadjuvant therapy. All patients were treatment-naive. The study adhered to the principles outlined in the Declaration of Helsinki. Written or oral informed consent was obtained from all patients.
